Cytokinetics CYTK Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's accrued expenses?
- Cytokinetics (CYTK) reported accrued expenses of $8.59M in Q1 2026.
- How has Cytokinetics's accrued expenses changed year-over-year?
- Cytokinetics's accrued expenses increased by 47.6% year-over-year, from $5.82M to $8.59M.
- What is the long-term trend for Cytokinetics's accrued expenses?
- Over 5 years (2020 to 2025), Cytokinetics's accrued expenses has grown at a 29.6% compound annual growth rate (CAGR), from $1.05M to $3.83M.
- What does accrued expenses mean?
- Costs the company has incurred but hasn't received a bill for yet.
- How do you interpret accrued expenses?
- Fluctuations often track with the scale of operations and the timing of R&D or administrative activities.
- How does accrued expenses compare across companies?
- Standard accounting practice; levels should align with operational activity.